Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aristo Bio-Tech and Lifescience's Enterprise Value for the quarter that ended in Mar. 2025 was ₹998 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aristo Bio-Tech and Lifescience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience EV-to-EBIT Related Terms
Aristo Bio-Tech and Lifescience EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aristo Bio-Tech and Lifescience EV-to-EBIT vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aristo Bio-Tech and Lifescience's EV-to-EBIT falls into.
Aristo Bio-Tech and Lifescience's current Enterprise Value is ₹1,090 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aristo Bio-Tech and Lifescience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a EV-to-EBIT of 14.60 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aristo Bio-Tech and Lifescience and its competitors.
Is Aristo Bio-Tech and Lifescience's EV-to-EBIT too high?
Aristo Bio-Tech and Lifescience's current EV-to-EBIT is 14.60. The Agriculture industry median EV-to-EBIT is 12.11. Aristo Bio-Tech and Lifescience's value of 14.60 is 20.6% above this industry median. Overall, Aristo Bio-Tech and Lifescience has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Aristo Bio-Tech and Lifescience's EV-to-EBIT compare to CTVA and CF?
Aristo Bio-Tech and Lifescience's EV-to-EBIT of 14.60 can be compared against companies in the Agriculture industry. The industry median EV-to-EBIT is 12.11. Aristo Bio-Tech and Lifescience's value of 14.60 is 20.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for an Agriculture company?
The median EV-to-EBIT among Agriculture companies is 12.11, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aristo Bio-Tech and Lifescience's current EV-to-EBIT of 14.60 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aristo Bio-Tech and Lifescience and its competitors. For the Agriculture industry, the median EV-to-EBIT is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aristo Bio-Tech and Lifescience's current EV-to-EBIT is 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aristo Bio-Tech and Lifescience stock overvalued right now?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a current EV-to-EBIT of 14.60. The current EV-to-EBIT is 14.60 and 20.6% above the Agriculture industry median of 12.11. Aristo Bio-Tech and Lifescience's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aristo Bio-Tech and Lifescience (NSE:ARISTO), the current EV-to-EBIT is 14.60 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.
59GF Score
Get the complete analysis for NSE:ARISTO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ARISTO has been successfully added to your 
